Amplia Therapeutics Shares Up After Entering Agreement to Conduct Ovarian Cancer Clinical Study

MT Newswires Live

May 11

Amplia Therapeutics (ASX:ATX) shares were up nearly 2% in recent trading on Monday after it said in a statement on Friday that it entered into an agreement with the Australia New Zealand Gynaecological Oncology Group to conduct a clinical study investigating its drug candidate narmafotinib in ovarian cancer.

The study will evaluate the safety of narmafotinib in combination with standard-of-care chemotherapy (carboplatin and paclitaxel).

It is expected to enroll around 15 to 20 patients with high-grade serous ovarian cancer, who demonstrate poor response to up-front standard-of-care platinum-based chemotherapy before planned interval debulking surgery.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2634524475"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634524475\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634524475?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 10:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634524475","market":"hk","top_or_hot":-1,"title":"Amplia Therapeutics Shares Up After Entering Agreement to Conduct Ovarian Cancer Clinical Study","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) shares were up nearly 2% in recent trading on Monday after it said in a statement on Friday that it entered into an agreement with the <a href=\"https://laohu8.com/S/ANZPH.AU\">Australia New Zealand</a> Gynaecological Oncology Group to conduct a clinical study investigating its drug candidate narmafotinib in ovarian cancer.</p><p>The study will evaluate the safety of narmafotinib in combination with standard-of-care chemotherapy (carboplatin and paclitaxel).</p><p>It is expected to enroll around 15 to 20 patients with high-grade serous ovarian cancer, who demonstrate poor response to up-front standard-of-care platinum-based chemotherapy before planned interval debulking surgery.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amplia Therapeutics Shares Up After Entering Agreement to Conduct Ovarian Cancer Clinical Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmplia Therapeutics Shares Up After Entering Agreement to Conduct Ovarian Cancer Clinical Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-11 10:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) shares were up nearly 2% in recent trading on Monday after it said in a statement on Friday that it entered into an agreement with the <a href=\"https://laohu8.com/S/ANZPH.AU\">Australia New Zealand</a> Gynaecological Oncology Group to conduct a clinical study investigating its drug candidate narmafotinib in ovarian cancer.</p><p>The study will evaluate the safety of narmafotinib in combination with standard-of-care chemotherapy (carboplatin and paclitaxel).</p><p>It is expected to enroll around 15 to 20 patients with high-grade serous ovarian cancer, who demonstrate poor response to up-front standard-of-care platinum-based chemotherapy before planned interval debulking surgery.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2634524475","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634524475","pubTimestamp":1778467518,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amplia Therapeutics  shares were up nearly 2% in recent trading on Monday after it said in a statement on Friday that it entered into an agreement with the Australia New Zealand Gynaecological Oncology Group to conduct a clinical study investigating its drug candidate narmafotinib in ovarian cancer.The study will evaluate the safety of narmafotinib in combination with standard-of-care chemotherapy .It is expected to enroll around 15 to 20 patients with high-grade serous ovarian cancer, who demonstrate poor response to up-front standard-of-care platinum-based chemotherapy before planned interval debulking surgery.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","ATX.AU":"AMPLIA THERAPEUTICS LTD","BK4139":"生物科技","LENZ":"Therapeutics","BK7067":"生物科技","BK4007":"制药"},"translate_title":"Amplia Therapeutics达成开展卵巢癌临床研究协议后股价上涨","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"ATX.AU":1},"content_text":"Amplia Therapeutics (ASX:ATX) shares were up nearly 2% in recent trading on Monday after it said in a statement on Friday that it entered into an agreement with the Australia New Zealand Gynaecological Oncology Group to conduct a clinical study investigating its drug candidate narmafotinib in ovarian cancer.The study will evaluate the safety of narmafotinib in combination with standard-of-care chemotherapy (carboplatin and paclitaxel).It is expected to enroll around 15 to 20 patients with high-grade serous ovarian cancer, who demonstrate poor response to up-front standard-of-care platinum-based chemotherapy before planned interval debulking surgery.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}